DESVENLAFAXINE 50 MG
DESVENLAFAXINE : 50 MG · DIN 02535106 · SANIS HEALTH INC
Health Canada status: MARKETED
What is DESVENLAFAXINE?
DESVENLAFAXINE 50 MG contains DESVENLAFAXINE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02535106, held by SANIS HEALTH INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 25-May-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DESVENLAFAXINE used for?
Symptomatic relief of major depressive disorder (MDD) in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02535106 |
|---|---|
| Brand name | DESVENLAFAXINE |
| Generic / active ingredient | DESVENLAFAXINE : 50 MG |
| Manufacturer | SANIS HEALTH INC |
| Strength | 50 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AX23 DESVENLAFAXINE |
| AHFS class | 90:24.16.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-May-2023 |
| Original market date | 2023-08-14 00:00:00 |
How is it administered?
Recommended starting dose: 50 mg once daily, with or without food. Maximum dose: 100 mg/day. Tablets must be swallowed whole; do not crush, chew, or divide. Taper gradually when discontinuing.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C (based on standard pharmaceutical practice for this type of product, though specific text was truncated in the provided snippet).
How is it supplied?
HDPE Bottles of 30, 100, and 500 tablets; Unit Dose Blisters of 100 (10 X 10) tablets.
Contraindications
Concomitant use with MAOIs or within 14 days of stopping MAOIs; hypersensitivity to desvenlafaxine, venlafaxine, or any ingredient in the formulation.
Warnings and precautions
Increased risk of self-harm and suicidal thinking. Risk of serotonin syndrome, sustained hypertension, and discontinuation syndrome. Caution in patients with cardiovascular or lipid disorders.
What can be used instead?
Other Canadian products sharing ATC code N06AX23 DESVENLAFAXINE. 20 of 28 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-DESVENLAFAXINE | 100 MG | TABLET (EXTENDED-RELEASE) | ANGITA PHARMA INC. | MARKETED | DIN 02525623 |
| AG-DESVENLAFAXINE | 50 MG | TABLET (EXTENDED-RELEASE) | ANGITA PHARMA INC. | MARKETED | DIN 02525615 |
| APO-DESVENLAFAXINE | 100 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02466996 |
| APO-DESVENLAFAXINE | 50 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02466988 |
| DESVENLAFAXINE | 100 MG | TABLET (EXTENDED-RELEASE) | SANIS HEALTH INC | MARKETED | DIN 02535114 |
| DESVENLAFAXINE | 100 MG | TABLET (EXTENDED-RELEASE) | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02554976 |
| DESVENLAFAXINE | 100 MG | TABLET (EXTENDED-RELEASE) | PRO DOC LIMITEE | MARKETED | DIN 02543680 |
| DESVENLAFAXINE | 50 MG | TABLET (EXTENDED-RELEASE) | PRO DOC LIMITEE | MARKETED | DIN 02543672 |
| DESVENLAFAXINE | 50 MG | TABLET (EXTENDED-RELEASE) | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02554968 |
| JAMP DESVENLAFAXINE | 100 MG | TABLET (EXTENDED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02495147 |
Who else supplies DESVENLAFAXINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DESVENLAFAXINE appears in 244 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.